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http:WHAT THIS STUDY ADDS
Patients with ilio-femoral or ilio-femoropopliteal DVT with prior silent PE or heart disease had an increased risk
of symptomatic PE during CDT treatment. For those patients, a prophylactic inferior vena cava ﬁlter may be
recommended. Screening for silent PE in DVT patients with increased risk of symptomatic PE may be beneﬁcial in
some patients, such as those with coexisting heart disease.Objective: The aim was to study the risk factors associated with symptomatic pulmonary embolism (PE) in
patients with deep venous thrombosis (DVT) in the lower limbs treated by catheter directed thrombolysis (CDT)
without inferior vena cava ﬁlter (IVCF) placement.
Methods: A total 266 patients with acute/subacute ilio-femoral, ilio-femoropopliteal, and femoropopliteal
thrombosis conﬁrmed by computed tomography venography or ultrasound Doppler were studied. All patients
were treated with CDT. CTPA (computed tomography pulmonary angiography) examination was performed in all
patients before thrombolysis. Patients with clinically suspected symptomatic PE were conﬁrmed by repeated
CTPA after treatment. The major outcome of this study was the occurrence of symptomatic PE events during CDT.
Results: During CDT, the incidence of symptomatic PE events was 4.9% (13/266). Patients with silent PE had a
higher risk of developing symptomatic PE (10/110, 9.1%) than those who had no prior PE (3/156, 1.9%);
multivariate analysis conﬁrmed this difference (OR 4.018, 95% CI 1.048e15.402). It was also found that patients
with previous heart disease had a higher risk of developing symptomatic PE (11/90, 12.2%) than those with no
prior heart disease (2/176, 1.1%). Multivariate analysis conﬁrmed that previous heart disease increased the risk
of developing symptomatic PE (OR 10.407, 95% CI 2.228e48.617). One patient who suffered from heart failure
and silent PE before CDT died of symptomatic PE (1/13, 7.7%).
Conclusion: The risk of developing symptomatic PE is most markedly increased in patients with previous silent PE
and heart disease. Selective rather than routine IVCF placement is an appropriate approach.
 2015 European Society for Vascular Surgery. Published by Elsevier Ltd. All rights reserved.
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Venous thrombosis is a common disease with the annual
incidence of around one case per 1000 people.1,2 About one
third of patients with primary deep venous thrombosis
(DVT) may develop silent (asymptomatic) pulmonary em-
bolism (PE).3,4 Catheter directed thrombolysis (CDT), which
uses a local delivery of plasminogen activating agents
directly into the thrombus, has been proved to be more
effective for thrombolysis and restoring venous patencyresponding author. Department of Vascular Surgery, 1st Afﬁliated
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, China.
il address: hw_cqmu@hotmail.com (W. Huang).
-5884/ 2015 European Society for Vascular Surgery. Published by
r Ltd. All rights reserved.
//dx.doi.org/10.1016/j.ejvs.2015.07.036than anticoagulation alone for patients with DVT.5,6 A
theoretical risk of this treatment is PE, which is caused by
clot dissolution, and the traditional view suggests that in a
patient with high risk of PE an inferior vena cava ﬁlter (IVCF)
should be placed. In patients treated by CDT, the incidence
of symptomatic PE has been reported as 4.5%; neverthe-
less, the incidence is less than 2% if treated only by anti-
coagulation with low molecular weight heparin (LMWH).7
However, whether an IVCF should be placed in patients
with DVT treated by CDT is still controversial. The aim of this
report is to retrospectively study the incidence of symp-
tomatic PE in patients with ilio-femoral, ilio-femo-
ropopliteal, and femoropopliteal DVT in the lower extremity
treated by CDT without prophylactic IVCF placement and to
deﬁne the risk factors associated with symptomatic PE.
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Population and study design
The incidence of symptomatic PE during CDT was retro-
spectively studied, and the risk factors which can increase
the occurrence of symptomatic PE were assessed. The in-
clusion criteria were as follows: (a) patients with symptom-
atic acute/subacute ilio-femoral, ilio-femoropopliteal, and
femoropopliteal thrombosis (conﬁrmed by CT venography or
duplex ultrasound at the hospital) and without clinical PE
symptoms treated by CDT without prophylactic IVCF place-
ment; (b) all patients underwent CTPA (computed tomog-
raphy pulmonary angiography) examination before starting
thrombolysis; (c) during thrombolysis, suspected symptom-
atic PE was conﬁrmed by repeated CTPA. All CTPA exami-
nations were performed on a commercially available helical
scanner (PQ 5000; Philips Medical Systems, Veldhoven, The
Netherlands) with the same acquisition parameters. Patients
were examined while in the supine position. Before CT ex-
amination, they were trained to breath hold for 20e40
seconds after full inspiration. Twenty seconds before CT
acquisition, an intravenous injection of iodinated contrast
medium was initiated at a ﬂow rate of 3 mL/s. Acquisition
started 2 cm below the top of the diaphragm and ended at
the upper border of the aortic arch, enabling visualization of
the heart and pulmonary arteries up to the sub-segmental
branching order. Scans were reconstructed at 5 mm in-
tervals with a soft tissue algorithm.
The following parameters were recorded: patient’s sex,
age, body mass index; presence of co-existing heart disease
(including myocardial infarction, heart failure, atrial ﬁbril-
lation, or valvular heart disease); and the side of the DVT in
the lower limb. Data were collected on previous cancer,
fractures, surgery, and immobility to determine whether
thrombosis had been provoked. Fatal PE, in the absence of
autopsy, was deﬁned as any death secondary to symp-
tomatic PE during the period of thrombolysis, in the
absence of any alternative cause of death.Thrombolytic therapy
Before the CDT procedure, LMWH was discontinued for at
least 8 hours to obtain an international normalized ratio <
1.5 in all patients. At the start of CDT, an intravenous bolus
dose of unfractionated heparin (UFH), 5000 U, was given
followed by a continuous intravenous UFH infusion at 15 U/
kg h.The UFH dose was adjusted to keep the activated partial
thromboplastin time (APTT) at 40e60 seconds during CDT.
Vascular access into the affected limb was achieved using
ultrasound guided entry into an appropriate vein, prefer-
entially the popliteal vein. The calf, femoral or common
femoral veins were other options for venous access. In the
study, thrombolysis was performed through the popliteal
vein in 199 cases, through the femoral veins or common
femoral veins in 45 cases, and through calf veins in 22 cases.
A 6F vascular sheath was typically inserted, through which
all subsequent catheter and wire exchanges were per-
formed. The wire and catheter were advanced above theproximal part of the thrombus. Thrombolytic drugs were
infused through a multiple side hole system with tip oc-
clusion (Unifuse system, Cook, Bloomington, IA, USA). In all
patients the thrombolytic agent was urokinase. Urokinase
was most commonly infused at a rate of 100,000 U/hour or
120,000 U/hour (range 80,000e140,000 U/hour). Treatment
duration and lytic doses were retrieved from medical re-
cords. Hemostasis was monitored by daily analysis of he-
moglobin, ﬁbrinogen, and platelet counts, and APTT was
monitored twice daily for adjustment of heparin dose.
During CDT, concomitant use of antithrombotic agents
other than UFH was discontinued.
Thrombolysis was assessed daily by venography. A
thrombus score was calculated for seven venous segments,
including the IVC, the common iliac vein, the external iliac
vein, the common femoral vein, the proximal and distal su-
perﬁcial femoral veins, and the popliteal vein. The thrombus
score was 0 when the vein was patent and completely free of
thrombus, 1 when partially occluded, and 2 when completely
occluded.The total thrombus score before and after lysis was
then calculated by adding the scores of the seven venous
segments before and after thrombolysis. The difference be-
tween the pre- and post-CDT thrombus scores was divided by
the pre-lysis score, resulting in the percentage of thrombol-
ysis achieved, where grade I 50%; grade II¼ 50e90%, and
grade III ¼ complete thrombolysis.8
Major bleeding was deﬁned as any clinically overt
bleeding that resulted in the cessation of therapy, further
hospitalization, a decrease of  2 g/dL hemoglobin, leading
to transfusion of  2 units of packed red blood cells,
retroperitoneal/intracranial/critical organ bleeding, or
death. Clinically relevant minor bleeding included, for
example, intervention for epistaxis, a visible large hema-
toma, or spontaneous macroscopic hematuria. All other
hemorrhages were categorized as trivial. A weight adjusted
full therapeutic dose of subcutaneous LMWH given twice
daily was initiated 1 hour after removal of catheters.Statistical analysis
Statistical analysis was performed with the SPSS 18.0 sta-
tistical package software. Continuous variables were sum-
marized as medians or means and standard deviations. The
chi-square test was used for comparison of categorical
variables. The inﬂuence of a number of continuous variables
on the major outcome was tested by a Student t test. Re-
sults with p < .05 were considered statistically signiﬁcant.
The dependence of each covariate on the outcome was ﬁrst
checked separately using the chi-square test. Covariates
with the signiﬁcance level of p < .05 were included in the
multivariate stepwise analysis. A two sided p < .05 was
considered to be statistically signiﬁcant.RESULTS
Characteristics of patients with DVT in the lower limb
In total 266 patients were enrolled between December
2011 to November 2014. Of these patients, 32 patients
Table 2. Outcomes of CDT for patients with DVT in the lower limb.
Clot lysis % (no.)
Grade III 61.6 (164/266)
Grade II 30.5 (81/266)
Grade I 7.9 (21/266)
Complications during CDT
Major bleeding 1.5 (4/266)
Minor bleeding 4.6 (12/266)
CDT ¼ catheter directed thrombolysis; DVT ¼ deep venous
thrombosis.
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had ilio-femoral (76.7%) thrombosis, and 30 patients had
femoropopliteal thrombosis (11.3%). A total of 213 pa-
tients were conﬁrmed by duplex scanning, 48 by CT
venography, and the other ﬁve patients were conﬁrmed by
both. All patients had CTPA examination before proceed-
ing with thrombolysis. Patient characteristics are shown in
Table 1.
Outcomes of CDT
A mean total of 3.1  0.7 million IU of urokinase was used
for each patient. The mean duration of thrombolysis was
29  6 hours. Grade III clot lysis was achieved in 164 of 266
patients (61.6%). Grade II was achieved in 81 of 266 pa-
tients (30.5%). Only 21 patients had grade I lysis or
persistent thrombosis (7.9%). There was no difference in the
duration of thrombolysis therapy between complete and
partial lysis (data not shown).
A total of 16 (6%) overt bleeding complications were
reported. Major bleeding occurred in four (1.5%) patients.
No immediate deaths were reported as a result of a major
bleeding complication. The outcomes of CDT are shown in
Table 2.
Incidence of symptomatic PE
During CDT 13 (4.9%) patients developed symptomatic PE.
The inﬂuence of several characteristics on the symptomaticTable 1. Characteristics of the patients with deep venous
thrombosis in the lower limb.
Characteristic DVT patients (266)
Age (years) 22e75 (median 46)
< 29 16
30e59 148
60e75 102
BMI 18.88e30.73 (mean 24.24)
< 24 129
24e26 81
> 26 56
Sex
Male 93
Female 173
DVT side
Right 117
Left 149
Previous heart disease
Yes 90
Heart failure 41
Myocardial infarction 28
Atrial ﬁbrillation 17
Valve disease 4
No 176
Unprovoked DVT
Yes 80
No 186
Silent PE
Yes 110
No 156
BMI ¼ body mass index; DVT ¼ deep venous thrombosis;
PE ¼ pulmonary embolism.PE is summarized in Table 3. The prevalence of symptomatic
PE showed no difference between the various age groups
(p ¼ .1) nor between the three BMI groups (p ¼ .77). PE
was found more frequently in men than in women (5.7% vs.
4.5%), but the difference was not signiﬁcant (p ¼ .76). More
patients were found to suffer from symptomatic PE when
the DVT was on the right side than when on the left (6.0%
vs. 4.0%, p ¼ .57). Among the 102 patients with unpro-
voked DVT in the lower limb, the incidence of symptomatic
PE was higher than in those patients with provoked DVT
(6.3% vs. 4.3%, p ¼ .54). In patients with previously diag-
nosed heart disease, symptomatic PE occurred in 11 of 90
patients (12.2%) compared with two of 176 patients (1.1%)
with no heart disease (p < .01). The incidence of symp-
tomatic PE in patients with silent PE was higher than those
patients with no PE (9.1% vs. 1.9%, p < .01).
Risk factors associated with the incidence of symptomatic
PE
The results of the stepwise logistic regression are summa-
rized in Table 4. The ﬁnal multivariate model showed thatTable 3. Univariate analysis for symptomatic PE during CDT.
Characteristic Symptomatic PE No PE p
Age (years)
< 29 1/16 15/16
30e59 11/148 137/148
60e75 1/102 101/102 .1
BMI
< 24 7/127 120/127
24e26 4/76 72/76
> 26 2/63 61/63 .77
Sex
Male 5/88 83/88
Female 8/178 170/178 .76
DVT side
Right 7/117 110/117
Left 6/149 143/149 .57
Previous heart disease
Yes 11/90 79/90
No 2/176 174/176 .000*
Unprovoked DVT
Yes 5/80 75/80
No 8/186 178/186 .54
Silent PE
Yes 10/110 100/110
No 3/156 153/156 .01*
Note. Comparisons between patients with vs. without the
symptomatic PE event: *p < .05. BMI ¼ body mass index; DVT,
deep venous thrombosis; PE ¼ pulmonary embolism.
Table 4. Multivariate analyses for symptomatic PE during the
period of thrombolysis.
Characteristic Odds ratio 95% CI
Previous heart disease
Yes/no 10.407 2.228e48.617
Silent PE
Yes/no 4.018 1.048e15.402
CI ¼ conﬁdence interval; PE ¼ pulmonary embolism;
VTE ¼ venous thromboembolism.
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lence of symptomatic PE. However, in this study, the age,
sex, BMI, the side of the DVT, and unprovoked DVT were not
correlated with the prevalence of symptomatic PE in pa-
tients with DVT in a lower limb treated with CDT.DISCUSSION
Current evidence has proved that CDT can reduce clot
burden and DVT recurrence and consequently prevents
post-thrombotic syndrome (PTS) compared with systemic
anticoagulation.5,9e12 In CDT treated patients with DVT in
the lower limb, the incidence of symptomatic PE has been
reported to be 4.5%; nevertheless, the incidence is less than
2% if treated only by anticoagulation with LMWH.7,13 In this
study it was found that the incidence of symptomatic PE
was 4.9% during CDT. However, in subgroup analysis, it was
found that the incidence of symptomatic PE events was only
1.9% in patients without prior silent PE. In contrast, the
incidence of symptomatic PE was 9.1% during CDT in pa-
tients with silent PE, much higher than that of patients
without silent PE, indicating that CDT did not increase the
occurrence of symptomatic PE events for patients without
prior silent PE. It has been reported that silent PE can in-
crease the risk of symptomatic PE during the period of
anticoagulation.14 However, there is little information about
whether silent PE can increase the risk of symptomatic PE
events during CDT. This study conﬁrmed that silent PE was a
risk factor for the incidence of symptomatic PE for patients
treated by CDT, indicating that CDT did not increase the
occurrence of symptomatic PE events for patients without
previous silent PE. In other words, for those patients with
previous silent PE, prophylactic IVCF may be recommended.
IVCFs are intended to prevent the passage of thrombus
to the pulmonary arteries and have been gaining popu-
larity.15e17 A review of trends over 21 years in the US Na-
tional Discharge Survey (1979e1999) and a Medicare
survey citing trends between 1999 and 2008 reported a
marked increase in the use of IVCFs,18e20 especially given
the retrievable nature of modern devices. IVCFs have been
advocated for patients undergoing pharmacologic and
pharmaco-mechanical thrombolysis of DVT due to the risk
of “breakaway” pulmonary embolization.21 In a prospective
analysis of 174 patients being treated with streptokinase for
DVT via a temporary ﬁlter catheter, emboli were detected
within the ﬁlter in 31.1%, one of which was more than
6 cm.22 In an analysis of 17 patients who received an IVCF
prior to treatment with CDT or pharmaco-mechanical
thrombolysis for DVT, a trapped thrombus was observedin eight patients (47.1%).21 However, controversy about
whether an IVCF is always required during CDT remains.
Indications for IVCF placement are based mainly on expert
opinion as there is a paucity of randomized controlled trials
to demonstrate which groups of people truly beneﬁt from
ﬁlter placement. Accepted indications include the presence
of acute venous thromboembolism with the inability to
administer anticoagulation medication or failure of anti-
coagulation.23 More controversial indications for IVCFs
include free ﬂoating thrombus, cancer patients, and as
primary prophylaxis in major trauma patients or surgical
patients at high risk of a DVT.24e28 In the clinical situation,
decisions to insert IVC ﬁlters that are outside the estab-
lished guidelines are common.29,30 The current study
conﬁrmed that silent PE can increase the risk for symp-
tomatic PE during CDT. The data also suggested that pre-
vious silent PE may be another indication for IVCF
placement for patients with DVT in a lower limb treated
with CDT.
It was also found that previous heart disease increased
the risk of symptomatic PE. There is little information to
support this.31,32 The analysis directly showed that the
incidence of symptomatic PE was 12.2% during CDT of pa-
tients with previous heart disease, much higher than that of
patients with no heart disease. Multivariate analysis also
conﬁrmed the result that patients with previous heart dis-
ease had an increased risk of symptomatic PE. This result
combined with previous reports suggested that previous
heart disease may be another indication for IVCF placement
for patients with DVT in a lower limb, especially in those
with previous silent PE.33,34
One patient with silent PE and previous heart failure died
during CDT. The cause of death was hypoxemia. The varia-
tions of pulmonary artery hemodynamics and the patho-
logical changes of vessel structure in patients with heart
failure may be the culprit, and pulmonary edema induced
by heart failure may make the situation worse, but further
studies are needed because there was no autopsy evidence.
However, for complicated pathologic changes in DVT pa-
tients with silent PE and previous heart failure, a preventive
vena cava ﬁlter may provide potential beneﬁts.
Some limitations of the study need to be addressed. First,
since this research was a retrospective study, the patients
known to be at high risk for PE had received IVC ﬁlters and
were excluded. Thus, there is potential selection bias. Sec-
ond, the aim of this study was to evaluate the risk factors
associated with symptomatic PE, so CTPA was not performed
for patients without PE symptoms during CDT.This may affect
the results. Further prospective studies are necessary for
deﬁnitive answers regarding the prevalence of symptomatic
PE and effectiveness of IVCF placement during CDT.
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Long-term Symptomatic Endoleak type 1a as a Result of Aortic Endograft
Material Fatigue
A.D. Giannoukas *, S. Koutsias
Vascular Surgery Department, University Hospital of Larissa, Faculty of Medicine, School of Health Sciences, University of Thessaly, Larissa, GreeceA 65-year-old man presented with acute lumbar pain following elective endovascular aneurysm repair using an Endurant
(Medtronic, Minneapolis, MN, USA) endograft 5 years previously. His 3-year follow-up with annual computed tomography
(CT) scan was clear. Over the last 2 years he was lost to follow-up because of concurrent lung carcinoma treatment. On the
current CT scan a type Ia endoleak was noticed due to partial detachment of the uncovered proximal stent from the graft
body (A), which was conﬁrmed during surgery for total graft explantation (B) and interposition of a Dacron aortoiliac (right)
and femoral (left) graft with a good outcome for the patient.
